CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's...
Hence then, the article about kelun biotech presents positive results of phase 3 clinical study optitrop breast02 for sacituzumab tirumotecan in advanced hr her2 breast cancer at 2025 esmo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO )
Also on site :
- Rosalía Shuts Down Kenan Thompson’s Idea for a Pop-Classical Album in Hilarious ‘SNL’ Promo: ‘That’s LUX’
- Viola Davis, 61, Opens Up About ‘Extremely Painful’ Health Condition for the First Time: ‘It Terrified Me’ (Exclusive)
- In 1924, Caesar Cardini ran out of kitchen supplies in a Fourth of July rush at his Tijuana restaurant; he tossed romaine with what was left, and the salad carries his name